Antimicrobial postexposure prophylaxis for anthrax: Adverse events and adherence

被引:112
作者
Shepard, CW
Soriano-Gabarro, M
Zell, ER
Hayslett, J
Lukacs, S
Goldstein, S
Factor, S
Jones, J
Ridzon, R
Williams, I
Rosenstein, N
机构
[1] Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Atlanta, GA 30333 USA
[2] New York Acad Med, New York, NY USA
关键词
D O I
10.3201/eid0810.020349
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We collected data during postexposure antimicrobial prophylaxis campaigns and from a prophylaxis program evaluation 60 days after start of antimicrobial prophylaxis involving persons from six U.S. sites where Bacillus anthracis exposures occurred. Adverse events associated with antimicrobial prophylaxis to prevent anthrax were commonly reported, but hospitalizations and serious adverse events as defined by Food and Drug Administration criteria were rare. Overall adherence during 60 days of antimicrobial prophylaxis was poor (44%), ranging from 21% of persons exposed in the Morgan postal facility in New York City to 64% of persons exposed at the Brentwood postal facility in Washington, D.C. Adherence was highest among participants in an investigational new drug protocol to receive additional antibiotics with or without anthrax vaccine-a likely surrogate for anthrax risk perception. Adherence of <60 days was not consistently associated with adverse events.
引用
收藏
页码:1124 / 1132
页数:9
相关论文
共 27 条
  • [1] [Anonymous], MORBIDITY MORTALITY
  • [2] Nonspecific medication side effects and the nocebo phenomenon
    Barsky, AJ
    Saintfort, R
    Rogers, MP
    Borus, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (05): : 622 - 627
  • [3] BRYANT SG, 1987, PHARMACOTHERAPY, V7, P125
  • [4] *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1008
  • [5] *CDCP, 2002, NAT PHARM STOCKP PRO
  • [6] *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1051
  • [7] Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1077
  • [8] Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P987
  • [9] Food Drug Administration, 2000, MED REV
  • [10] POSTEXPOSURE PROPHYLAXIS AGAINST EXPERIMENTAL INHALATION ANTHRAX
    FRIEDLANDER, AM
    WELKOS, SL
    PITT, MLM
    EZZELL, JW
    WORSHAM, PL
    ROSE, KJ
    IVINS, BE
    LOWE, JR
    HOWE, GB
    MIKESELL, P
    LAWRENCE, WB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) : 1239 - 1243